MapLight Therapeutics Q1 net loss $60.7M; completes enrollment in two Phase 2 trials

MapLight Therapeutics, Inc.

2026-Q1 EPS reported -$1.34

Net loss of $60.7M in Q1 2026 vs $22.3M YoY; R&D expenses $53.7M, G&A $10.8M.
Cash and investments $395.2M as of March 31, 2026; expected to fund operations through 2027.
Enrollment completed in Phase 2 ZEPHYR trial (schizophrenia, n=307); topline data expected mid-August 2026.
Last patient visit completed in Phase 2 IRIS trial (autism, n=161); topline data also expected mid-August 2026.
Phase 2 VISTA trial for Alzheimer's disease psychosis ongoing; topline expected H2 2027.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MapLight Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $60.7 million.

Period: first quarter ended March 31, 2026
Net income: Net loss was $60.7 million
Result: reported results

Exact text from the filing

On May 14, 2026, MapLight Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

MapLight Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-224067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.